parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.06 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in kupffer cells	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	3 Parkinson's trials, 0 stopped	1.00
literature PubMed	48 Parkinson's papers of 5,423	0.49
pathways Reactome	3 pathways; mostly immune signalling	0.90

No case: the score is under the bar. Receipt 4688

receipt 4696: MAF in dopamine neurons, braak

power: full sample -0.03 (p 0.894, n 18), 95% CI -0.49 to +0.44. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.05 (p 0.834, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.05 (p 0.834, n 18). could be the mix.
skeptic: leave-one-out range -0.16 to +0.08, sign flips 8; without severely affected donors -0.03 (p 0.894, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for MAF in dopamine neurons.

case closed: nothing better to follow up.

receipt 4695: MAF in microglia, braak

power: full sample +0.22 (p 0.389, n 18), 95% CI -0.28 to +0.62. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.23 (p 0.365, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: +0.36 (p 0.142, n 18). could be the mix.
skeptic: leave-one-out range +0.10 to +0.34, sign flips 0; without severely affected donors +0.22 (p 0.389, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for MAF in microglia.

case closed: nothing better to follow up.

loading the receipts